Harmonized regulation of research with human stem cells in Europe has shaped innovation in regenerative medicine. Findings from a Phase III academic clinical trial of an autologous cell procedure illustrate the obstacles a multinational trial faces. A typology of the obstacles encountered, may help other teams embarking upon trials. The findings throw light on the situation of clinician-scientists in clinical innovation, as the expertise to run scientific trials is very complex. The innovation route of clinical translation takes insufficient account of the interdependencies between multiple social and cultural factors from outside the laboratory and the clinic. For ethical reasons, however, academic and business routes to stem cell treatments ought to be enabled by the regulators. Suggestions arise: how academics can prepare for trials, that academic research needs better institutional support, and that new models of medical innovation may need to be developed for regenerative medicine.
Introduction
The landscape of regulations applying to innovations and medicine, and especially with human cells and tissues is chequered and shapes the socio-political environments in which Regenerative Medicine (RM) proceeds. Europe has very strict governance regimes in place that prevent rogue marketing of cell treatments, but also add a high logistical and cost burden to the development of future therapies. Progress in approved clinical treatments is slow, and pathways toward them are sought that solve the conundrum of pressing consumer demand and patient need, the problems arising from existing forms of regulatory oversight, and the long time and high financial stakes involved in bringing new treatments into the clinic via the staggered model of the scientific clinical trial (CT). Medical translation from the laboratory bench to the bedside has become increasingly fraught with problems whilst it has become imperative for science to demonstrate its applicability [1, 2, 3] .
Salter, Zhou, and Datta [4, 5] discuss four innovation models for stem cell (SC) therapies. Many call for ways of overcoming the conflicting interests tied to the unsatisfactory present regulatory situation in order to advance RM and control a mushrooming industry that puts at risk patient lives and the reputation of the field of RM. But, similar to other direct-toconsumer markets in biomedicine, the lack of global reach of legal or regulatory interventions to govern emerging consumer markets seems to leave three other options: One are professional standards often issued by transnational bodies such as the ISSCR mentioned above, another are quality certificates similar to ISO standards for product (14) , a third is public engagement to educate publics about the risks and costs of unproven stem cell treatments [15] . This article presents details on how the current European regulations.
Model I is called
This article presents findings from a sociological study alongside an ongoing multinational
European Phase III stem cell CT. The findings illustrate how difficult translation can be, and that the common focus on knowledge transfer and application in translational medicine underestimates the impact of regulation and cultural diversity on the process of clinical [11, 15] .
Methods and Case Study
Social scientific studies have accompanied stem cell research from its inception in the late 1990s to the present [16] . Human embryonic stem cells (hESC) attracted critical debate amongst experts and the public, largely because of the contested use of human embryos for the derivation of hESC lines [17, 18] . The potential for a new form of therapy led to changes in national laws or to exemptions from prohibitions on embryo research [19, 20] . By contrast, bone-marrow-derived stem cells had been used clinically for decades [21] . [22, 23] . The scientific aim of the trial is to establish whether mortality after severe acute myocardial infarction (AMI) decreases following with this stem cell procedure [24] . BAMI has been recruiting patients in Belgium, the Czech Republic, Denmark, Finland, Germany, Italy, the Netherlands, Spain, and the UK.
The following summative presentation of issues faced in BAMI is organized into four themes: (1) Regulatory Approval, (2) Regulatory Standards and National Differences, (3) Cultural Issues, and (4) Scientific Innovation in Academic Medicine -Time and Money. I
close with a future perspective on how these issues might be addressed to advance not only industrial but also academic SC therapy innovation in Europe. Detailed accounts of the empirical findings with direct quotations and extended sociological discussions have been published [25, 26] . This concise presentation with regard to the debate on RM regulation highlights problems that especially affect academic research teams and research on stem cell medical procedures. It may provide a useful roadmap for other groups preparing future RM CTs. to the trial protocol, approval renewal procedures began to add to delays -this is an aspect to which I will return below.
Practically problematic was fulfilling the requirements set by regulation. The streamlined implementation rules of the EUTCD came into effect between the planning and starting of for the use in AMI CTs Phase I and II are available in major research hospitals. The PIs had conducted such trials locally, using their local haematology laboratory for cell preparation.
The BAMI trial had been planned and costed accordingly. Fulfilling this much higher and very specific protocol for cell processing required access to other laboratories that were qualified not just to sort the cells according to size but to turn the patients' BMSC into something like a standardized medicinal product, even though it would only be used for the cell donor him-or herself.
1b: ATIMP and GMP
Putting these requirements into practice became a major cause of delay of patient recruitment. Previously it had been assumed that six PI partners could offer cell processing centres. When checking these laboratories, only three qualified fully with the licensing and manufacturing standards now in place. Acquiring a licence was too laborious and costly and thus it became necessary to transport the cells to the few ATMP laboratories to which BAMI had access (in Germany, Spain, and Denmark), and to start negotiating the use of laboratories 
1c: VHP and Regulatory Regress
New regulatory rules always come with teething problems [27] . Moreover, endotoxin-free tubes are difficult to obtain as there is only one manufacturer of them in Europe. The specific requirements for the tubes used for transporting bone marrow resulted in lengthy discussions, and ultimately an amendment to the BAMI protocol: the technical requirement to use endotoxin-free tubes was dropped.
Important to note here is that preparing a multinational trial requires detailed familiarization with the regulatory procedures likely to be in force when the trial is to start. Securing both access to the cell processing facilities needed and staffing capacity are important as well. Cell transport licences may be required, which alone took up to 8 months to obtain in some countries after EMA and VHP approval, before trial site initiation could even be considered.
The growing number of ATMP/GMP certified laboratories in Europe will help in avoiding such costly and logistically difficult problems in the future for those who have easy access.
Findings: 2. Regulatory Standards and National Differences
BAMI PIs new that standard clinical practice treatment of acute AMI was the same across
Europe. This is, however, not the case for all devices and drugs that may be used. A specific drug that prevents blood clotting and is used in BAMI had not been approved for use by the national authorities in one of the partner countries. The use of this drug was part of the treatment protocol and the PI in the respective country had to apply for it. The PI did successfully gain an exemption for restricted use of the drug in the BAMI trial from the National Authorities. Supply was arranged through another BAMI National Coordinating Centre (NCC). Other partners were troubled by the cost of this drug. Solutions were bulk
buying and distribution at a reduced price. The logistics and licensing for this arrangement in adherence with the trial protocol required extensive preparation.
Another requirement is that the bone marrow aspirating and SC reinjecting clinicians must hold a good clinical practice (GCP) certificate. In some EU countries those need to be obtained once, in others, such as the UK, they need to be renewed biannually. Since this certification is part of the harmonized procedure, and since BAMI has been headed by a hospital in the UK, all staff in BAMI undertaking these tasks needed recent GCP certificates.
Despite the BAMI trial office making renewal as easy as possible, completing it was not readily achieved at all sites.
Alignment in all aspects of the trial protocol must be assured. At the start the clinicians leading BAMI were, unsurprisingly, not fully aware of some of the mundane bureaucratic licensing issues the teams would encounter.
Findings: 3. National and Cultural Environment Issues
In addition to regulatory approvals of the CT and its protocols and sorting out technical compliance with the standards set, the clinical teams in each country and location also need to have local hospital ethics approval for the trial.
Having EMA and VHP approval in place should ease that process, but during this step another set of issues emerged that affected implementation and cost time. These I call cultural issues, because they are variations in conventions and practices at the different sites.
They relate to the way in which the local health care system is organized, how doctor-patient relations are understood, and how such environmental issues of attitudes and institutional organization affect informed consent practices. The local ethics application includes approval of the Patient Information Sheet, and the Informed Consent Sheet, both usually prepared in the local language. The ethics committee also makes sure that insurance for the trial is adequate in their eyes. These points among others affected one or more BAMI sites.
3a: Patient Information Sheets
The English language sheets were translated and adapted to local requirements and submitted to the local clinical ethics committee. It was found that the principles concerning how much and what information patients ought to receive differ widely across European countries.
Some felt that the information to potential patients provided in the UK is too detailed and too medical in language to be appropriate. Patient Information Sheets were adapted to fit local practice. sheets in the countries is not the same, so certified translations of these sheets still need to be provided.
3b: Insurance:
Insurance of the trial turned out to be an issue beyond ensuring that patient interests were protected. The overall trial insurance had to be complemented by additional insurances in some countries. The trial sponsor has to insure the trial, including risks to patients. In some locations the annual renewal practice for the trial insurance, customary in the UK for all insurance contracts, was deemed insufficient. It was a matter of concern that patients would each be in the trial for over two years and thus that renewal might become difficult should any incidents occur. Additional patient insurance had to be bought in these countries (e.g. in
Germany, Italy and Spain). Many NCCs required the BAMI insurance policy to be translated
Preproof Author Version, accepted for publication in Regenerative Medicine on 27. July 17 publication in Volume 1 of double Special Issue expected 2 nd half of Sept. 2017 11 into their own language so that it could be checked by the ethics committees. This too came at a cost -financially and in staff time. For the sponsor as well as for the clinical teams running the NCCs it has been tricky to discover what exactly needs to be done for each locality and to whom one should speak. Whilst each NCC is familiar with how the process works in their country, finding out enough detail to put insurance in place so that every partner's needs were satisfied was an effort.
The lesson from this is that an unexpected amount of very detailed and locality-specific knowledge is required that is not readily available in places of academic research. What exactly has to be insured and the ways in which patients ought to be informed differ across the BAMI partner countries according to local cultural conventions and ethical perceptions.
Having acquired much of this expertise through a trial and error approach has advanced the knowledge of the BAMI NCC staff enormously. But many NCC staff remarked on the huge difference in experience and effort between running an industry sponsored trial, where all these cultural issues are taken care of by the funder, and this academic trial. For readers interested in how our interviewees described these cultural problems, more detail on these findings have been published [26] . Timing is crucial and BAMI was unfortunate being affected by regulatory changes that required different local infrastructure to conduct the research. But the availability of fully GMP certified laboratories has increased markedly with strong support from the European Commission. Without easy access to such facilities research in RM is now impossible.
Time delays and lack of funds affected other parts of the trial in the long-term and required re-approval by EMA and VHP. Not only do staff take on new posts over such long periods of time, but also both the standard therapy in the patient control group, as well as the materials and equipment used in the trial, might change. With time these risks rise. If another innovation in AMI patient treatment were to be implemented while the trial is ongoing, the patients treated previously and those treated after that change could not be compared to each other -but it would be ethically impermissible not to treat patients to the best standard of care. This is one of the reasons why Phase III trials are likely to be conducted across many countries. They must try to recruit the high patient numbers for a specialized treatment and a narrowly defined patient group.
Similarly, equipment needs to remain the same throughout according to regulatory demand.
Therefore, it seemed sensible to purchase from the outset sufficient equipment to treat all patients. Having to buy equipment from a new production batch would require re-approvalscientific validity is deemed at stake. However, every item of clinical and pharmaceutical equipment has a use-by date after which the manufacturer no longer guarantees that it still meets all quality specifications. Sterility and efficacy of solutions in vials and pharmaceuticals used in the cell processing laboratories are the primary concern here.
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Because of the time delays, BAMI confronted both problems: that batches of equipment ran out of use over the protracted recruitment period. Protocol changes and re-approval by the EMA and NCAs via VHP were necessary. Those added to the overall delay, not least because in some countries NCAs require that patient recruitment must be halted whilst re-approval is sought, which in some countries can still take many months, even though it should not.
Time delays breed time delays, and the European harmonized regulatory setting and its VHP, whilst intent on simplifying approval procedures for multinational studies and speeding up RM innovation, add to the problems once delays or changes have begun to emerge in a CT.
Discussion
The findings from the experiences in BAMI illustrate how European harmonized regulation affects trial implementation. Laying out these effects should contribute several aspects to the ongoing debate about regulatory regimes for RM, two of them I will highlight. The current European regulatory situation may be a serviceable bulwark against markets for unproven cures but it also hampers academic research consortia who try to develop autologous therapies within the strict framework of the CT paradigm, Model 1 in Salter and colleagues' terminology [4, 5] . The paradigm itself is thus put into question for therapy pathways such as autologous, which are not industry sponsored. In order for local, affordable SC therapies to become part of a validated clinical treatment regime with reimbursement options, such therapies might need to be developed possibly taking other existing models as an inspiration.
BAMI was intended as a scaling up from Phase I or II trials to a Phase III trial and the range of new challenges this entails was unexpected, especially in the multinational setting. Large numbers of patients and specialised industrial production modalities for the trialled therapeutic are required for scientific validity of the procedure trialled. European regulations have effectively aligned standards of scientific medical research (i.e., generalisability and statistical data on efficacy) with standards of product development, more so with recent regulatory changes to the EUTCD and its ATMP amendment.
The institution of the clinic is highly integrated with other societal practices. This makes it a difficult space for scientific innovation in the form of the big clinical trial. Structurally, problems of the kind described above are inevitable, the larger and more multi-sited the trial the more so. Taken together, the problems encountered, the difficulties in overcoming them, and the human cost in terms of staff time and effort all seem to suggest that academic Phase 
Conclusions
The role of academic medicine in the development of future treatments cannot be answered on the basis of this case study. But it should be apparent that the judgement of clinical practitioners is critical at every stage of medical innovation, be that an exemption situation in a first patient application or the assessment of the benefits of a new treatment to large patient populations beyond statistical significance. Therefore, it would seem sensible, given the many trials with autologous cell procedures that academics are keen to investigate, to include their perspective and approach when searching for commercially viable stem cell RM. This is underlined in Europe when considering the ethical point of view and recognising the moral tensions over stem cell research. The high public and political investment that has been afforded this field, points to a political need for regulation that enables the trialling of the diverse therapeutic approaches that scientists and clinicians have reasons to pursue in the interest of best patient care.
From the case study it is impossible to draw conclusions regarding whether academic teams can or cannot run Phase III trials. To take an informed view on this would require a much wider study including trials that are not affected by the triple set of regulations in which Clinical Trial regulation and diverse hospital ethics are added to by strict regulation of the medical treatment as such. The third regulatory apparatus is specific for the field of cell therapies and one entry point at which the complex process of developing a suitable regulatory infrastructure that serves RM and patients might need more work. The nonnegotiable binary classification between somatic cell therapy or ATMP probably needs more transparency in its application and refinement and openness for discussion given that clinician scientists advance new ways of using cells and tissues therapeutically. The current regulatory set-up must be refined, and a wider consultation should be engaged in about the EUTCD classification of all non-homologous autologous stem cell procedures as ATMP Another potentially substantial advantage from such a public expertise hub would be that the knowledge about differences in health care systems, insurance provisions, information needs, translation issues, the contracts GMP laboratories offer, and so forth to become public property and accumulate in the European public sphere. That would save a lot of future work and time and might also help to better understand how the remits of different sets of regulations intersect with national institutional contexts and thus help better policy making in the health sector in the future. The interest of the regulators need to be in tune with the interests of patients and health care providers. Otherwise the scientific innovation pathway in Europe will be designed to exclude academic research based on medical experience that carries low risks but potentially high benefits.
On a more practical note, as long as the surrounding conditions persist, the case study might help other teams of clinician scientists to approach their trials with more preparation. For academic researchers embarking on a multinational SC trial, the following brief summary of issues to consider might prove useful, especially when not working with a CRO:
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• Discussion with the regulator in the preparatory stage might be useful, to be certain that you are familiar with the regulatory procedures that will be in force when the trial starts.
• Access to licensed cell processing facilities must be arranged, affordable and staffed.
• If IMP transportation is necessary, consider all licencing and export permission needs.
• Clinical practice on the ground varies in many little ways. Harmonized protocols require detailed alignment and extra capacity to adapt for National Competent Authority or local ethics approval requirements
• Cultural issues differ by location, state, country, traditions. Provisions must be available to cater for local needs so that they can be aligned to scientific and VHP protocols
• Time delays and the multiple ways in which they affect the cost of equipment, staff, and cause more time delays and regulatory re-approvals should be avoided if at all possible
• A very big team that makes a timely concerted effort might be preferable but requires a firm management structure to govern a large consortium of partners with different roles
Executive Summary
• This report on the problems encountered during an academic European stem cell trial could be helpful to clinicians setting out on similar enterprises.
• Clinician-scientists' pursuit of research based on their medical experience can be stifled by the current regulatory regime in packed in Europe.
• Multiple regulations covering stem cell use are simultaneously effective in containing marketing of unproven treatments but also the clinical translation of autologous stem cell treatments, which is hampered additionally by lack of industry sponsorship.
• One might state ethical contradictions between the public support, morally and financially, for stem cell research and the limiting effects of regulation on particular directions of this research that should be addressed by regulators, in cooperation with scientists and publics.
• One effective intervention to overcome the structural disadvantage of academic research and autologous stem cell translation could be a free CRO hub for such research at the EMA.
• The findings support the questioning of scientific innovation by clinical trial and the debate about new pathways for safe, efficacious and valid stem cell regenerative medicine.
